close Icon

Targeting B cells in treatment of autoimmunity.

Franks SE, Getahun A, Hogarth PM, Cambier JC

  • Journal Current opinion in immunology

  • Published 05 Oct 2016

  • Volume 43

  • Pagination 39-45

  • DOI 10.1016/j.coi.2016.09.003


B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.